TP53 C135F

CI-VAR-00000272Explore in graph →CIViC 2719

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TP53 C135F	MDM2 Inhibitor AMGMDS3	Predictive	D	Supports Resistance	3	submitted	EID10076 A subset of 58 cancer cell lines with unaltered TP53 are sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor.… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Unmapped disease4unmapped disease
TP53 C135F	(functional)	Functional	D	Supports Loss Of Function	2	submitted	EID9440 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.